🇩🇰 Denmark Country × Condition
cardiovascular diseases Clinical Trials in Denmark
Active clinical trials for cardiovascular diseases with research sites in Denmark. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 5 // Recruiting: 5 Phases: Phase 3 // Updated: Daily
Total Trials
5
Recruiting Now
5
Country
🇩🇰 Denmark
Active Trials in Denmark (5)
NCT06325618
Recruiting
Lymphedema, Low-grade Inflammation and the Vasculature in Turner Syndrome
Enrollment
150 pts
Country
🇩🇰 Denmark
University of Aarhus
View Trial → NCT04950218
Recruiting
Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis
Enrollment
1,000 pts
Country
🇩🇰 Denmark
Herlev and Gentofte Hospital
View Trial → NCT05633810 Phase 3
Recruiting
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
Enrollment
10,000 pts
Country
🇩🇰 Denmark
Montreal Heart Institute
View Trial → NCT06203860
Recruiting
The Cardio-Metabolic Clinic
Enrollment
1,600 pts
Country
🇩🇰 Denmark
Odense University Hospital
View Trial → NCT05647876
Recruiting
A Longitudinal Study to Identify Mechanisms of Menopause on Cardiovascular Disease Risk
Enrollment
200 pts
Country
🇩🇰 Denmark
University of Copenhagen
View Trial → Frequently Asked Questions
How many cardiovascular diseases clinical trials are active in Denmark?
There are currently 5 active clinical trials for cardiovascular diseases with sites in Denmark, of which 5 are actively recruiting patients.
How can I join a cardiovascular diseases clinical trial in Denmark?
To join a cardiovascular diseases clinical trial in Denmark, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Denmark directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are cardiovascular diseases trials in Denmark?
Active cardiovascular diseases trials in Denmark span Phase 3. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.